Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Immunotherapy has improvedsurvival outcomes of patients with advanced melanoma. Lower gastrointestinal tract immune-related adverse events (irAEs) are common during treatment; however, gastritis is not frequently observed. Herein, we report a case of severe cytomegalovirus (CMV)-related gastritis in a patient treated with ipilimumab and nivolumab for metastatic melanoma. This report presents a 60-year-old woman with stage IV BRAF wild-type melanoma. t. After the second course of ipilimumab-nivolumab, the patient reported epigastric discomfort after meals, anorexia, and subsequent nausea, vomiting, epigastric pain, and weight loss. Disease staging with PET/CT scan showed very good partial response and diffuse gastroduodenitis. The patient underwent esophagogastroduodenoscopy, showing severe esophageal candidiasis and diffuse hemorrhagic, edematous, and ulcerative mucosa in the whole gastric wall. Biopsies of the gastric wall were obtained. Before receipt of the final pathology report, the patient was empirically started on corticosteroids based on the clinical suspicion of immune-related gastritis, without improvement of symptoms. The hematoxylin-eosin staining demonstrated active gastritis with diffuse nuclear cytopathic viral inclusions in epithelial and interstitial cells; CMV infection was confirmed with immunohistochemical staining. The patient startedganciclovir and fluconazole, with rapid improvement of symptoms. This case presents a rare instance of CMV gastritis in a patient receiving combined anti-PD1 and anti-CTLA4 , in the absence of immune-suppression to manage an irAE. In the case of suggestive symptoms of irAEs, a high index of clinical suspicion is required to rule out concomitant or isolated infective disease. Guidelines for prophylaxis and treatment of these patients are needed, to optimize treatment results.
Identifiants
pubmed: 38768445
doi: 10.1097/CMR.0000000000000981
pii: 00008390-990000000-00147
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381:1535–1546.
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283–2289.
Postow MA, Sidlow R, Hellman MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378:158–168.
Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017; 28:2860–2865.
Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology 2017; 70:558–567.
Kobayashi M, Yamaguchi O, Nagata K, Nonaka K, Ryozawa S. Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc 2017; 86:915–916.
Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J 2017; 4:e57.
Samonis G, Bousmpoukea A, Molfeta A, Kalkinis AD, Petraki K, Koutserimpas C, et al. Severe gastritis due to nivolumab treatment of a metastatic melanoma patient. Diagnostics (Basel) 2022; 12:2864.
Elmasry M, Dong B, Rios C, Breaux A, Miller D. Delayed hemorrhagic gastritis caused by immunotherapy in a patient with metastatic melanoma. Am J Med Sci 2022; 364:343–346.
Ruiz AR Jr, Borum ML. Cytomegalovirus hemorrhagic gastritis. AIDS Patient Care STDS 2001; 15:1–5.
Yeh PJ, Chiu CT, Lai MW, Wu R-C, Kuo C-J, Hsu J-T, et al. Cytomegalovirus gastritis: Clinicopathological profile. Dig Liver Dis 2021; 53:722–728.
Lu J, Firpi-Morell RJ, Dang LH, Lai J, Liu X. An unusual case of gastritis in one patient receiving PD-1 blocking therapy: coexisting immune-related gastritis and cytomegaloviral infection. Gastroenterology Res 2018; 11:383–387.
Kim H, Ha SY, Kim J, Kang M, Lee J. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Curr Oncol 2020; 27:e436–e439.
Hulo P, Touchefeu Y, Cauchin E, Archambeaud I, Chapelle N, Bossard C, et al. Acute ulceronecrotic gastritis with cytomegalovirus reactivation: uncommon toxicity of immune checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer. Clin Colorectal Cancer 2020; 19:e183–e188.
Vallejo Rivera SR, Nicolás Niza L, Bonilla López L, Díaz Concepción J. Severe gastritis in a patient treated with immunotherapy: immune-mediated or reactivation of cytomegalovirus? Rev Esp Enferm Dig 2022; 10:578–579.
Sugiyama Y, Tanabe H, Matsuya T, Kobayashi Y, Murakami Y, Sasaki T, et al. Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review. Endosc Int Open 2022; 10:E982–E989.
Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22:76–98, Table of Contents.
Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, et al. CD4 T cell-derived IFN-γ plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog 2016; 12:e1005667.
Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1)- deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A 2010; 107:13402–13407.
Rowe JH, Johanns TM, Ertelt JM, Way SS. PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes. J Immunol 2008; 180:7553–7557.
Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. J ImmunoTher Cancer 2014; 2:19.
Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 2015; 38:212–215.